Nasus Pharma Ltd (NSRX)
Score window: Apr. 15, 2025 to Apr. 14, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Aug. 8, 2025 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd. has submitted a request to the SEC for the acceleration of the effectiveness of its Registration Statement No. 333-288582, aiming for it to become effective on A… | Read Filing EDGAR |
| Aug. 8, 2025 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd has submitted a request for the acceleration of the effective date of its Registration Statement on Form F-1, aiming for it to become effective on August 11, 2025… | Read Filing EDGAR |
| Aug. 7, 2025 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd. has submitted a response to the SEC's comment letter dated August 6, 2025, regarding their Amendment No. 1 to the Registration Statement on Form F-1. The company… | Read Filing EDGAR |
| Aug. 6, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed Nasus Pharma Ltd.'s amended registration statement and provided several comments that need to be addressed before the statement can be finalized. Key points i… | Read Filing EDGAR |
| Jul. 28, 2025 | CORRESP | Neutral/Informational | Moderate | Nasus Pharma Ltd. has submitted a response to the SEC's comment letter dated July 16, 2025, regarding their Registration Statement on Form F-1 filed on July 9, 2025. The correspon… | Read Filing EDGAR |
| Jul. 16, 2025 | UPLOAD | Concern from SEC | Moderate | The SEC has reviewed Nasus Pharma Ltd.'s registration statement on Form F-1 filed on July 9, 2025, and has requested additional information regarding the enantiomeric stability st… | Read Filing EDGAR |
| May. 20, 2025 | UPLOAD | Concern from SEC | Moderate | The SEC has reviewed Nasus Pharma Ltd.'s amended draft registration statement and has issued a comment regarding the cover page disclosures. They require clarification that the tr… | Read Filing EDGAR |
| May. 7, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed Nasus Pharma Ltd.'s Amendment No. 5 to their Draft Registration Statement on Form F-1 and has issued several comments requiring further clarification and revi… | Read Filing EDGAR |
| Apr. 22, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed the amended draft registration statement for Nasus Pharma Ltd. and has provided several comments that need to be addressed. Key issues include the need to rev… | Read Filing EDGAR |